Abstract: Blood coagulation could be recognized as intrinsic inflammation. The coagulant mediators (FVIIa, FXa, thrombin (FIIa), FXIIa) and fibrin(ogen) activate cellular signaling, eliciting the production of cytokines, chemokines, growth factors, and other proinflammatory mediators. Hypercoagulability with elevated coagulant mediators would certainly trigger hyper-inflammatory state not to mention about the direct hypercoagulable actions on thrombosis, and platelet and complement activations, all of which contribute to inflammatory events. Furthermore, anticoagulant's antiinflammatory effects readily reinforce the proposal that blood coagulation results in inflammation. The observations on protease activated receptor (PAR) activation and PAR antagonists modulating inflammation are also in line with the concept of coagulation-dependent inflammation.
INTRODUCTION
Inflammation plays a "diverging-converging" role in widely involving a broad spectrum of disease statuses and complications regardless of their pathogeneses. For instance, depression has even been recognized an inflammatory state [1] . Heterogeneous chronic obstructive pulmonary disease readily manifests as respiratory inflammation [2] somewhat similar to asthma outcome.
Inflammation could be generally associated with elevated proinflammatory network involving cytokines (e.g., TNF , IL-1 , IL-6, etc.), chemokines (CXCs, CCLs, etc.), adhesion molecules (MCP-1, ICAM, VCAM, selectins, etc.), growth factors (e.g., VEGF, PDGF, GM-CSF, etc.), and other inflammatory mediators (e.g., CRP, PGE2, LTs, PAF, histamine, matrix metalloproteinases (MMP), bradykinin (BK), calpain, complements, ET-1, ATII, etc.). The pleiotropic effects of these inflammatory mediators include activating T/B cell maturation/differentiation, non-immune cells, cellular signaling, and gene expressions. Inflammation damages surrounding tissues, contributes to angiogenesis/tumorigenesis, and manifests as many symptoms. Accordingly, combating inflammation becomes strategic approaches for relieving many disease complications. Anticytokine approaches, including reception suppression by soluble cytokine receptors and/or receptor analogous, offer broad clinical benefits to human inflammatory diseases [3] such as asthma [4] , autoimmune disorders [5] (e.g., rheumatoid arthritis (RA), Crohn's disease, and psoriasis), and many others. Anti-VEGF Ab shows antagonism against RA by blocking VEGF reception and cytokine (TNF-and IL-6) production [6] . Anti-Pselectin antibody attenuates inflammation [7] .
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The source of inflammation is heterogeneous. Clinical studies readily demonstrate the close relationship of infection with inflammation. In most cases, inflammation in response to infection is essentially part of innate and adaptive immune systems. There is a perception that inflammation is most likely mediated by Toll-like receptors (TLR) [for reviews, see ref. 8, 9] receiving signals from either exogenous pathogen or endogenous danger -associated molecular patterns as a consequence of diverse infection or tissue injury/damage, respectively. Through MyD88-dependent or independent cellular activation of transcription factors (e.g, AP-1, NF B, and IRF3), proinflammatory genes are upregulated thereby resulting in local and/or systemic inflammation. Accordingly, TLR7/9 antagonists for immune-mediated inflammatory diseases have been reported [10] . mammals and other animals. However, often excessive or uncontrolled clot production leads to thrombosis shutting off blood flow that supplies oxygen and nutrients to cells. The resulting cell death manifests as stroke or heart attack. Coagulation has also been recognized an independent risk factor for atherosclerosis; fibrin stimulates plaque growth. There are two coagulation pathways essentially proceeding as extracellular signaling cascades. The inducible extrinsic pathway plays an integral role [15] , while the intrinsic pathway is constitutive facilitating blood coagulation merging with the extrinsic pathway at the point of tenase. The extrinsic but not intrinsic pathway is responsible for the initiation of thrombin generation and fibrin production [16] .
Extrinsic Pathway
Integral membrane glycoprotein: tissue factor (TF; CD142) initiates the extrinsic pathways, which is susceptible to in vivo upregulation by inflammation [for review, see ref.
17], vascular injury (i.e., protein disulfide isomerase) [16, 18, 19] , or advanced glycated end products under hyperglycemia. TF expression is mediated by the activations of signaling kinases (e.g., PTK, PKC, MAPK) and transcription factors (e.g., AP-1, Egr-1, NF B) while negatively correlating to intracelluar cAMP level [for review, see ref . 17] . Nitric oxide (NO) synthases and cyclooxgyenase (COX)1/2, however, seem to have nothing to do with TF expression [17] . In some clinical or pathological conditions, TF shed from vascular cells known as circulating plasma TF associated with microparticles also results in hypercoagulability and increased thrombotic risk [20, 21] . The microparticles involving selectin glycoprotein ligand 1 (PSGL-1) are captured by P-selectin to the sites of activated endothelium.
A series of zymogen activations take place on phospholipid-rich cell surfaces in a vitamin K and Ca+2 -dependent fashion [12, 16] . Upon FVII binding, TFdependent FVII activation leads to FVIIa formation; this active serine protease triggers sequential proteolyses of FX and prothrombin to generate active serine proteases: FXa and thrombin (FIIa), respectively. FIIa is responsible for cleaving fibrinogen (FBG); the resulting fibrin is further polymerized and consequently cross-linked by FXIIIa, thereby producing insoluble blood clots (Fig. 1A) . There are accessory loops for promoting the propagation of clotting. The initial FIIa formation activates FV and FVIII to form FVa and FVIIIa respectively, which activates tenase for fueling blood coagulation in the absence of TF [for review, see ref. 16].
Intrinsic Pathway
In the complementary intrinsic pathway (contact system) [for review, see refs. [22] [23] [24] , the coagulation cascade involves high molecular weight kininogen (HK)-dependent prekallikrein (PKK)/kallikrein (KK) regenerating cycle for FVIIa-dependent FXII activation (Fig. 1B) . The resulting FXIIa subsequently activates FXI following with the activation of FIX so that the intrinsic tenase shunts into the major extrinsic pathway in contribution to FXa generation [16] . The role of FXII (Hageman factor) in thrombogenesis, however, remains largely unclear.
Its upregulation is associated with many infectious and inflammatory conditions including severe falciparum malaria [25] , meningococcal septic shock [26] , sepsis [27] , Rhinovirus infection [28] , Staphylococcus aureus infection [29] , LPS [30, 31] , and complement activation [32] . Others such as pregnancy [33] , estrogen [34] , and artifact thawing/freezing [35] also activate contact coagulation.
BLOOD COAGULATION-INTRINSIC INFLAMMATION
The contribution of blood coagulation to inflammation could result from coagulant mediators, thrombosis, complement activation, and platelet activation. The close clinical links of coagulation with inflammation have been reported in sepsis [36] , DIC [37] , inflammatory bowel diseases [38] , lung diseases [39] including acute lung injury, acute respiratory distress syndrome and pneumonia [40] . Clinical studies implying the relationship of coagulation with inflammation showed that natural anticoagulant (e.g., activated protein C (APC), antithrombin (ATIII)) deficiencies are often associated with sepsis [41] , DIC consequences [42] , and inflammation [43] . C-1 inhibitor deficiency is also susceptible to inflammation and septic shock [44] , and the deficiency is often associated with increased vascular permeability [45] , a biomarker for inflammation.
Furthermore, anti-TF Ab shows anti-septic action [46] , which lays the foundation for coagulation-dependent inflammation. TF and FVIIa receptor/ligand interactions induce proinflammatory effects in macrophages [47] . Convincingly, the role of TF in proinflammation comes from the demonstration that recombinant soluble TF (sTF1-219) readily induces inflammation in vivo arthritis model with elevated plasma IL-6 and paw swelling, which is accompanied by fibrin production and platelet activation [48] . In addition, FVII deficiency protects against acute inflammation [49] , while elevated plasma level of FVIIa shows significant correlations to CRP and IL-6 [50] . Administration with recombinant FVIIa enhances IL-6 and -8 productions in healthy human subjects [51] . A receptor protein, gC1qR/p33 [52] , initiates PKK activation to KK for complement activation, and B-1/B-2 receptors [53] are responsible for the transduction of bradykinin (BK) proinflammation (Fig. 1B) .
Proinflammatory Mediator Production by Coagulant Mediators

PAR Activation Leading to Inflammation
PAR activating peptides elicit a broad spectrum of inflammation, which is consistent with the notion of coagulation-dependent inflammation.
PAR-1 Activation
An activating peptide (TRAP) enhances IL-6 [54] , PGE2 [55] , PGDF or P-selectin expression [56] . Another activating peptide (SFLLRN) induces the production of IL-6 [57] , -8 [58] , iNOS [59] , PGE2 [57] , MCP-1 [58] , NO [60] , or Pselectin [61] . SFLLKNPNDKYEPF elicits the expression of ICAM [62] and VEGF [63] . A recent study has reported that activated protein C (APC) activates PAR-1 to induce MCP-1 expression in EC [64] .
PAR-2 Activation
Tryptase or trypsin elicits the production of TNF- [65] , IL-1 [65] , IL-6 [65] [66] [67] or IL-8 [67, 68] and increases [Ca+2] i [68] . Its signaling also activates Erk [67] , AP-1 [67] , c-Jun [67] , p38 MAPK [67] , or NF B [68] . Apart from enhanced PI hydrolysis [69] , a PAR-2 activating peptide (SLIGKV) not only elicits [57] IL-6, -8 and PGE2, but also activates p38 MAPK [70] and MEK/Erk [71] to upregulate TNF-secretion [72] , PGE2 production [55] , and Erk activation [73] . Enhanced NO production [60] or P-selectin expression [74] by SLIGRL (activating peptide) accounts for muscle relaxation or leukocyte rolling, respectively. Agonist proteinase-3 (PR3) enhances IL-8, MCP-1 and ICAM-1 expression [75] . An in vivo comparison of null mutant (PAR-2 -/-) with wide-type (PAR-2 +/+) mice consistently indicates that PAR-2 is responsible for the induction of IL-6, ICAM-1 and E-selectin expression [76] . Diverse PAR-2 actions also go beyond this review's inflammation focus, involving pigmentation, vasodilation, pain/itch, IBS transmission, etc.
PAR-3 Activation
A peptide (TFRGAP) [77] induces Erk1/2 activation and [Ca+2] i , while SFNGGP [55] slightly elicits PGE2 release.
PAR-4 Activation
A peptide (GYPGQV) [57, 78] elicits TNF-, IL-6, -8 or PGE2 production. GYPGKF enhances PGE2 production [55] , [Ca+2] i , and platelet aggregation [79] . AYPGKF [80] activates p38 MAPK, PLC, and SrC.
FVIIa
In TF-expressing cells, FVIIa elicits VEGF [81] and activates PAR-2 to enhance SMC migration [82] , MAPK phosphorylation, and [Ca+2] i mobilization [83] . Enhanced IL-8 expression in response to FVIIa is mediated by PAR-2, facilitating cell migration [84] . In addition, PAR-2-mediated FVIIa signaling stimulates ET-1 synthesis [85] .
FXa
FXa signaling elicits IL-6 [86, 87] , IL-8 [86] or MCP-1 [55, 86] expression, which is PAR-1/3-dependent. PAR-2-dependent FXa signaling induces the expression of IL-6
[87]/-8 [86] , PDGF or MCP-1 [86] as well as Erk1/2 activation [73] .
FIIa
FIIa upregulates the production of IL-6 [52, 86, [88] [89] [90] , IL-8 [86] , TGF- [91] , MCP-1 [86, 87, 89] , PDGF [90] , bFGF [90] , ICAM-1 [62] , P-selectin [91] , or VEGF [63, 92] . PAR-1-dependent FIIa signaling enhances proinflammatory actions including NF B activation [62] , intracellular Ca+2 ([Ca+2] i ) mobilization, Erk1/2 phosphorylation [92] , iNOS [57] , COX-2 [94] , MMP-9 [95] , and PI hydrolysis [69] . FIIainduced PAR-1 signaling of IL-6, IL-8, MCP-1, PGE2 production and NF B activation is apparently sphingosine kinase 1-dependent [96] .
Fibrin
TLR 4 is proposed to mediate FBG pro-inflammation [97] including IL-6 and MCP-1 production [88] . Fibrin and its fragments elicit IL-1 [98] , IL-6 [99] , IL-8 [100] and ICAM [100] expression through undefined mechanism(s).
FXIIa
Proinflammatory effects of FXII activation are largely mediated by KK and BK generation [101] . In the PKK/KK/ HK regenerating loop, FXII undergoes autoactivation to FXIIa that further activates PKK to KK [102] (Fig. 1B) , subsequently releasing BK. gC1qR/p33, a membrane-bound receptor protein binding to HK, initiates PKK activation to KK in the presence of Zn+2 and FXII [52, 103] , thereby serving as a molecular bridge between contact activation and complement systems.
KK-Dependent Complement Activation
Proinflammatory KK directly activates not only complement components C3 and C5 [104] , but also C1 esterase (Fig. 1B) leading to inflammation via the classical complement activation [104, 105] . As the result of complement activation, it leads to NF B activation, the transcription and expression of adhesion molecules (VCAM-1, ICAM-1 and E-and P-selectins), production of IL-8 and MCP-1, platelet activation, and platelet-leukocyte aggregation, all of which represent inflammation [for review, see ref . 106] . KK also cleaves HK to liberate BK [105] , another proinflammatory mediator (see below section 3.1.6.2.). It, however, remains largely unknown whether PARs mediate KK proinflammatory action.
BK Release
Proinflammatory mediator BK (Arg-Pro-Pro-Gly-PheSer-Pro-Phe-Arg) is known as a major contributor to the innate inflammatory response. Derived from HK through the direct catalysis by KK (Fig. 1B) , BK is responsible for vasodilatation, increased vascular permeability, and inflammatory pain [104, [107] [108] [109] .
The involvement of BK in inflammatory process has been demonstrated in disease status [for review, see ref.
109]. BK proinflammation is largely mediated by its inducible B1 receptor or constitutive B2 receptor [53] . More specifically, B2-receptor is responsible for swelling and pain, while B1 receptor is specific in hyperalgesia. These G protein coupled receptors initiate complex intracellular signaling cascade involving adenylate cyclase, PLC, Ca+2 signal, MAPKs, etc., leading to NO and prostaglandin production.
BK through B1 receptor promotes ICAM/VCAM expression [110] ; B1 receptor activation also induces TNF-and IL-1 release [111] . Through B2 receptor, BK induces COX-2 expression in aortic vascular smooth muscle cells [112] involving the activation of MAPK p42/p44, PKC, and NOS. COX-2 products (e.g., TXA 2, PGE 2 ) have inflammatory properties. BK via B2 receptor induces MMP-2 production [113] .
Concerning intracellular activation, BK generally upregulates MAPK [114] [115] [116] , NOS [117] , and JAK/STAT signaling [118] . BK induces IL-6 [119] and IL-8 [120] expression, which is mediated by ERK1/2 and p38 MAPK activation in AP-1-dependent fashion [119] .
Complement Activation and Inflammation
KK in the intrinsic pathway activates complement components ( Fig. 1B ; also see section 3.1.6.1). In addition, FIIa could directly activate C5 and C3 [121] . Platelet activation resulting from coagulation also engages in complement activation (see section 3.3.).
Complement activation readily engages in virtually all phases of an acute inflammatory reaction including the increase in vascular permeability, extravasation of leukocytes, and chemotaxis. Complement activation presents inflammation [106] , eliciting an array of proinflammatory mediators including upregulated mRNA levels of CRP, TF, COX-2, TNF, E-selectin, ICAM, VCAM, I B , IL-1 , IL-1 , IL-8, and PAI-1. C1q is able to induce the production of IL-8, while C5a elicits IL-3 and MCP-1 production. C5b-9 induces IL-6/IL-8 production and the expression of AP-1 and NF B.
Platelet Activation and Inflammation
As a direct consequence of blood coagulation, platelet activation is primarily mediated by FIIa [122] . Platelet activation [122, 123] per se releases a broad spectrum of cytokines, adhesion molecules, growth factors, chemokines, and other inflammatory mediators. For cell neighboring effects, activated platelets result in activations of vascular cells such as endothelial cells, smooth muscle cells, lymphocytes, etc., which leads to local/systemic inflammation.
Apart from FIIa reception, other platelet receptors such as GPIb/IX/V, P-selectin, PSGL-1, CD40, gC1qR, and IIb 3 integrin participate in the progression of inflammatory conditions [124] . Interestingly, platelet activates C5 [125] , while C3 activation is mediated by C1q-dependent classical pathway [125] ; all represent inflammatory events [106, 121] . In addition, platelet activation results in aggregation and fibrin recruitment for thrombosis [16] that also contributes to inflammation (see below section 3.4.).
Thrombosis and Inflammation
The close association of thrombosis with inflammation has previously been reviewed by Esmon [126] , which is in line with hypercoaguability presenting the high tendency of thrombogenesis [13] and thrombotic contributions to inflammation [for review, see ref . 127] . In these regards, platelet activation and aggregation play roles in inflammation as described in the above section 3.2. & 3.3. The notion of profibrinolysis via plasminogen activation showing antiinflammation could be in further agreement with thrombosis-dependent inflammation [128] .
ANTAGONISM AGAINST INFLAMMATION DERIVED FROM BLOOD COAGULATION
Blood coagulation could become a target for antiinflammation ( Table 1) . Convincing evidence demonstrates natural anticoagulants and their analogs resulting in antiinflammation. Mounting observations also reveal antiinflammatory benefits resulting from anticoagulation ( In addition, APC exerts a profibrinolytic effect by inactivation of PAI-1 and inhibition of thrombin activated fibrinolytic inhibitor (TAFI) activation, which makes APC strong anti-thrombotic. As the result of the respective inhibitions on intrinsic tenase and prothrombinase for downregulating FXa and FIIa generation, APC thereby inactivates the production of IL-1, -6, -8 or TNF- [129] . APC is recognized one of the effective anti-inflammatory agents in clinical application. APC consistently reduces septic mortality and blocks DIC upon E. coli infection in either animal or human models [130] [131] [132] [133] . In animal models, recombinant human soluble thrombomodulin (TM) prevents LPS-induced pulmonary vascular injury, inhibiting leukocyte activation [134, 135] and accumulation [136, 137] . In view of TM being a cofactor of FIIa, its facilitation of PC activation could further support anti-inflammatory significance in relation to APC anticoagulation.
Tissue Factor Pathway Inhibitor (TFPI)
With respect to its ability to directly inhibit FXa followed by a feedback inhibition on TF/FVIIa complex, natural anticoagulant TFPI suppresses coagulation-dependent IL-8 production [138] or VCAM-1 expression [139] . In VSMC, TFPI reduces the autocrine release of PDGF-BB, MCP-1 and MMP-2 in response to FVIIa and FXa [140] . Its coagulationindependent action includes the direct suppression in TNF-, IL-6, and IL-8 production [141] , reducing mortality from E. coli septic shock in baboons. TFPI also directly interferes with LPS reception [142] . The failure in human studies [143] [144] [145] , however, warrants further research to clarify any clinical anti-inflammatory potential.
Antithrombin III (ATIII)
ATIII mediates pentasaccharide and heparin actions to inhibit FXa and FIIa, respectively. ATIII blocks FXainduced IL-6, IL-8, MCP-1, ICAM/VCAM, and E-selectin expressions [146] in addition to arresting FIIa-induced (PAR-1-dependent) VEGF release [92] and MCP-1 expression [147] . Apart from inactivating NF B [148] , AT III direct antiinflammatory action includes the suppression in INF-and ILs (e.g., 1, 2, 4, 6 & 8) production, which is mediated by enhanced PGI production and diminished inducible nitric oxide synthase (iNOS) [149] . However, the discrepancy exists concerning the survival rate beings improved in baboons [150] but not in severe human sepsis treated with the high dose of ATIII [151] . Further research warrants verifying its anti-inflammatory potential.
Warfarin
Also known as Coumadin or Acenocumarol, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one is an inhibitor of the synthesis for vitamin K-dependent clotting factors [12] . It suppresses the reductases for vitamin K regeneration that is a cofactor for the posttranslational carboxylation of glutamates to form gammacarboxyglutamates (Gla). The Gla domain is essential for phospholipid membrane anchoring and Ca +2 binding, which is present in the N-terminal of coagulation zymogens such as FII, FVII, FIX, FX, PC and PS [152] . Namely, warfarin generally depresses the functions of the clotting factors, thereby blocking global coagulation. Its antiiflammatory effect has been demonstrated in 1979 [153] . Oral warfarin significantly reduces IL-6 at day 15 [154] ; further investigation warrants exploring broad anti-inflammatory benefits, if any.
FVIIa Inhibition
Recombinant nematode anticoagulant protein c2 diminishes coagulation-dependent IL-6 and IL-8 productions [51] . Active site-inhibited FVIIa depresses LPS-inducible plasma levels of TNF- [144] , IL-6 [155] [156] [157] , and IL-8 [156, 157] . FVIIai abolishes VIIa signaling of Erk1/2 phosphorylation [83] in TF-expressing cells, while it suppresses sTF-induced inflammation in vivo model [48] . A small molecule BCX-3607 (TF/FVIIa inhibitor) also decreases IL-6 level in an endotoxemia mouse model [158] . 
FXa Inhibition
LMWH, enoxaparin, or DX9065a suppresses P-selectin, TNF-, IL-6 [159] , or MCP-1 [160] expression, resulting in depressed platelet activation [161] and leukocyte adhesion to EC [162] . A direct inhibitor (ZK-807834) blocks FXa signaling of eliciting IL-6 [87] . The anti-inflammatory effects of a newer anticoagulant rivaroxaban, however, remain largely unknown.
FIIa Inhibition
Heparin shows a variety of inflammatory potentials [for review, see ref. 163 ]. Heparin-bonded circuit prevents the increases in IL-6 and IL-8 in CPB patients without any effect on P-selectin [164] , while heparin bolus reduces neutrophil activation without affecting platelet aggregation [165] . Heparin and delteparin downregulate PAR-1 cleavage [166] , blocking PAR-1-mediated VEGF release in response to FIIa [92] .
Direct FIIa inhibitor (hirudin) binds to FIIa active site and prevents PAR-1 from cleavage [166] , thereby diminishing FIIa signaling in ICAM/VCAM expression [167] and elicitation of VEGF [63, 92] , IL-6 [168] , IL-8 [58] , or MCP-1 [58] . Hirudin suppresses sTF1-219-induced inflammation [46] . A hirudin analog (lepirudin) alleviates LPS-induced platelet activation [169] , and an active site inhibitor (melagatran) diminishes P-selectin expression [166] . Whether dabigatran could show any inflammatory effect warrants further study.
Antiinflammation by Blockade of Contact System
Consistent with the fact of FXIIa and KK being proinflammatory (section 3.1.6.), PA (urokinase) readily downregulates contact system with the consequence of lowering BK production and complement inactivation, accounting for its prevention of inflammation [128] .
FXIIa Inhibition
C-1 inhibitor, a protease inhibitor of the serpin family, downregulates contact coagulation by inactivating FXIIa, showing antiinflammation [102, 170] . ATIII-bound heparin and heparin sulfate inhibit FXII activation [171] . Ecotin is a potent inhibitor for FXIIa [172] .
KK Inhibition
Antiinflammatory contribution of KK inhibition is essentially mediated by blocking complement activation. C-1 inhibitor inactivates KK [102, 170] together with its ability to directly suppress complement C-1 [173] , showing diverse anti-inflammatory effects.
A recombinant small protein Eecallantide (DX88) [174] , based on the first Kunitz domain of human TFPI, is a potent and specific inhibitor of plasma KK; DX88 reverses the increased vascular permeability in C-1 inhibitor deficient mice. Ecotin [172] and Aprotinin [175] also directly inhibit KK and suppress BK release. However, anti-inflammatory effects by such inhibitors have not been reported thus far. 
BK Inhibition
REMARKS
Coagulation-dependent inflammation is revealed by which coagulant mediators are proinflammatory (Fig. 1) and anticoagulation is of anti-inflammation (Fig. 2) . Furthermore, coagulation-mediated platelet and complement activations readily present an array of inflammation (Fig. 3) . Hypercoagulation per se elicits elevated generation of FVIIa, FXa, FIIa, FXIIa, KK, and BK as well as fibrin overproduction, all of which in turn initiate cellular activation and signaling for inflammation (Fig. 1) . Both extrinsic and intrinsic pathways in fact play diverging as well as converging roles in proinflammation. Such vicious cycle linking blood coagulation to inflammation mutually refuels each other, ensuring hypercoagulability as well as hyperinflammatory (Fig. 2) . In these regards, blood coagulation could become a target for antiinflammation.
With respect to its thrombogenic as well as proinflammatory natures, it is not surprising that hypercoagulability triggers diverse cardiovascular complications. Namely, hypercoagulation extends one arm for thrombotic consequence and the other for inflammatory events. A paradigm: circuit (Fig. 3) Table 1 summarizes possible approaches to antiinflammation in relation to its blood coagulation-dependence. Apart from anticoagulants described in the above section 4, antagonism against complement components, PARs, cytokine reception, or gC1qR/p3 could be expecting to achieve anticoagulation, antiinflammation, antithrombosis, and cardioprotection. Even nutrient such as antioxidant curcumin suppressing TF expression could attenuate such coagulation-dependent inflammation.
Anticoagulation not only blocks thrombogenesis, but also arrests the coagulation-inflammation cycle (Figs. 2, 3) . The biopharmaceutical applications of anticoagulant development could be several-fold. (1) Anticoagulation certainly confers intervention remedy by offsetting the induced extrinsic hypercoagulability resulting from inflammation, vascular injury, or circulating TF microparticles. (2) Anticoagulation could provide broad spectrum of anti-inflammatory relevance regarding the operational coagulation-inflammation vicious cycle. (3) In view of hypercoagulability driving the circuit linking thrombosis and inflammation (Fig. 3) , anticoagulants block the coagulation-inflammation cycle to interrupt the coagulation-inflammation-thrombosis circuit, showing cardioprotection. The ability of PAR1 and 2 to induce TF [177] reveals not only coagulation-dependent inflammation but also diverging and converging roles of TF in refueling the cycle [17] . It remains challenging that selective upstream antagonism (i.e., inhibition on TF-dependent FVII activation) arrests only the extrinsic hypercoagulability to prevent thrombotic complication instead of blocking the constitutive intrinsic coagulation for hemostasis, which would effectively suppress inflammation while avoiding bleeding episode. 
